Intercept Pharmaceuticals, Inc. Logo

Press Release

<< Back
Oct 24, 2018
Intercept to Announce Third Quarter 2018 Financial Results on October 31, 2018

NEW YORK, Oct. 24, 2018 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its third quarter 2018 financial results prior to market open on Wednesday, October 31, 2018. The announcement will be followed by a conference call and audio webcast hosted by Intercept management at 8:30 a.m. ET to discuss the results.

Webcast information for this event will be available on the investor page of Intercept’s website at http://ir.interceptpharma.com. Archived webcasts will be available on Intercept’s website for approximately two weeks.

About Intercept
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. Founded in 2002 in New York, Intercept has operations in the United States, Europe and Canada.

       
CONTACT
       
For more information about Intercept, please contact:
       
       
      Mark Vignola
       
      +1-646-747-1000
       
      investors@interceptpharma.com 
       
       
      Media inquiries: media@interceptpharma.com

Intercept Pharmaceuticals, Inc. logo

Source: Intercept Pharmaceuticals, Inc.